^
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive: A2 - Guideline
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FOLFOX
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
CLDN18.2 expression
Esophageal Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Esophageal Adenocarcinoma
paclitaxel
Resistant: C3 – Early Trials
HER-2 positive
Esophageal Adenocarcinoma
carboplatin
Resistant: C3 – Early Trials
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Adenocarcinoma
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Adenocarcinoma
DKN-01
Sensitive: C3 – Early Trials
GRB7 positive
Esophageal Adenocarcinoma
trastuzumab + carboplatin + paclitaxel + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ERCC1 negative
Esophageal Adenocarcinoma
SOX
Sensitive: C3 – Early Trials
HER-2 positive
Esophageal Adenocarcinoma
nivolumab + trastuzumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Esophageal Adenocarcinoma
durvalumab
Sensitive: C3 – Early Trials
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
TP53 mutation
Esophageal Adenocarcinoma
APR-246
Sensitive: D – Preclinical